Company intelligence / Profile preview

HOOKIPA Pharma

Ownership: Public · HOOK
Development stage: Phase 2

Overview

HOOKIPA Pharma develops novel immunotherapies using engineered arenaviruses to induce robust antigen-specific T cell responses. Its lead program HB‑200 targets HPV16+ head and neck cancer and has shown promising response rates in combination with Keytruda in early trials. The company also has a next-generation therapeutic vaccine for HIV in collaboration with Gilead that recently completed Phase Ib enrollment. Preclinical assets include a multi-KRAS targeted therapy for solid tumors[6][8][10].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Viral vector-based immunotherapies (arenavirus vectors)Therapeutic vaccines
Industry: Biotech

Drug pipeline

13 assets

HB-201

12 more assets in the full pipeline.

Request access →

Partnerships

Gilead Sciences – collaboration on functional cures for HIV and hepatitis B[3][4][6]Roche – previously collaborated on KRAS-mutant cancers; partnership ended earlier in the year[8]

Financials

Market cap: $14.4M
Total revenue: $6.8M
Enterprise value: $-19.3M

Beyond the preview

Go deeper on HOOKIPA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HOOKIPA Pharma.

Explore the full profile